-
J Clin Oncol: Efficacy of devarumab± tramimumab and chemotherapy in first-line treatment of metastatic non-small cell lung cancer
Time of Update: 2022-11-14
In summary, compared with chemotherapy alone, devarumab combined with chemotherapy significantly prolonged progression-free survival in patients with metastatic non-small cell lung cancer.
In summary, compared with chemotherapy alone, devarumab combined with chemotherapy significantly prolonged progression-free survival in patients with metastatic non-small cell lung cancer.
-
A DMD patient died after receiving CRISPR gene-editing therapy, raising concerns about the future of gene-editing therapies
Time of Update: 2022-11-14
Recently, a 27-year-old Duchenne muscular dystrophy (DMD) patient named Terry Horgan tragically passed away after receiving CRISPR gene-editing treatment delivered by an adeno-associated virus (AAV9) vector, and although it is not clear the real cause of Terry Horgan's death and whether it is related to CRISPR, its death has undoubtedly raised concerns and questions about the future of CRISPR gene-editing therapy.
-
【CSCO 2022 Preview】Metaverse positioning technology combined with photodynamic targeted comprehensive treatment of glioma
Time of Update: 2022-11-14
com/s/DnYz-PHIWv8JDgA1B8zl8Q Glioma refers to tumors originating from brain glial cells, is the most common primary intracranial tumor, the 2021 edition of WHO central nervous system tumor classification will divide brain glioma into grade 1~4, grade 1, 2 for low-grade glioma, grade 3, 4 for high-grade glioma.
-
J Clin Oncol: Long-term prognosis for pembrolizumab monotherapy for PD-L1-positive NSCLC
Time of Update: 2022-11-14
02885 KEYNOTE-042 is a phase III randomized trial with initial results showing that pembrolizumab monotherapy significantly prolongs overall survival (OS) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a previously untreated PD-L1 tumor proportion score (TPS) of ≥1% compared with platinum-based chemotherapy.
-
When genetic sequencing can save lives, how can it be slow?
Time of Update: 2022-11-14
The HUAWEI CLOUD AI Gene Platform based on AI and big data provides high-performance, reliable, and cost-effective gene sequencing computation, storage, analysis, and AI capability support, standardizing and executing the scientific research process, thereby helping to speed up gene sequencing, improve efficiency, and reduce costs.
-
World J Urol: Predictor Survey of Prostate Cancer When MpMRI is Negative
Time of Update: 2022-11-14
Researchers from Germany recently published an article in World J Urol evaluating the predictors of prostate cancer (PCa) when mpMRI is negative.
biopsy can be avoided in selected patient populations (mpMRI negative) (higher age, prostate volume and free PSA levels, and lower PSA density) if adequate follow-up care is ensured.
-
Nature Cancer cover study: Revealing a new mechanism to overcome immune checkpoint inhibitor resistance
Time of Update: 2022-11-05
Links to papers: style="display: none;">Patients with EGFR mutation-activated non-small cell lung cancer (NSCLC) are not sensitive to immune checkpoint inhibitor therapy, which is the bottleneck of lung cancer immunotherapy.
-
【Advanced Science】Li Bin of Guangzhou Medical University and others have discovered a potential new mechanism to inhibit the occurrence of colorectal tumors!
Time of Update: 2022-11-05
Therefore, the research team believes that NU2058 is a potential novel anti-cancer drug with low toxicity in patients with CRC with β-catenin signaling activation.
Therefore, the research team believes that NU2058 is a potential novel anti-cancer drug with low toxicity in patients with CRC with β-catenin signaling activation.
-
The 2022 CBCS Essentials Guide is here, what does Professor Yu Keda think?
Time of Update: 2022-11-05
This recommendation is based primarily on the results of the PHEDRA study [1], a phase III clinical trial to evaluate the efficacy and safety of pyrrotinib/placebo + trastuzumab + docetaxel for neoadjuvant therapy for HER2-positive breast cancer 。 According to the results presented at the 2021 San Antonio Breast Cancer Congress (SABCS), the total pathological complete response (tpCR) rate assessed by the Independent Review Committee (IRC) in the pyrrotinib group was 41%, significantly higher than the 22% (P respectively.
-
Target Offering| NSCLC bimonthly review of the second issue
Time of Update: 2022-11-05
·Editor: EchoReview: Fish ballsTypesetting: UniExecution: UniThis platform aims to deliver more medical information to healthcare professionals.
END·Editor: EchoReview: Fish ballsTypesetting: UniExecution: UniThis platform aims to deliver more medical information to healthcare professionals.
END·Editor: EchoReview: Fish ballsTypesetting: UniExecution: UniThis platform aims to deliver more medical information to healthcare professionals.
-
Meta-analysis of clinical trials for the treatment of recurrent glioblastoma
Time of Update: 2022-11-05
Article published online in the February 2021 issue of Neurooncol Adv. Research methods The investigators searched for phase 2 and 3 clinical RCTs reporting relapsed GBM treatment in databases such as MEDLINE (PubMed and Ovid), Embase and Web of Science up to 1 July 2019, including at least 20 patients in each group, according to the Priority Reporting Entry (PRISMA) guidelines of systematic reviews and meta-analyses.
-
【News】The ninth live broadcast of the "Drug Precision" series ended successfully, focusing on drug targets, and pharmaceutical company celebrities talked about the progress of DLBCL targeted drug research and clinical treatment!
Time of Update: 2022-11-05
Director Liu Wei, Hematology Hospital, Chinese Academy of Medical SciencesFinally, Dr. Wang Chunyang, Senior Translational Medicine Manager of Genetron, gave a speech entitled "Exploration and Application of ctDNA in Precision Diagnosis and Treatment of DLBCL Patients".
-
Research frontier EphB2 inhibitors combined with PD-1 monoclonal antibody in mUC
Time of Update: 2022-11-05
GuideBladderurothelial carcinoma is a common tumor in urology, and the 5-year survival rate of newly diagnosed patients is low, while the median survival of patients after first-line platinum-based chemotherapy is about 1 year, and the prognosis is poor.
-
Current gastric cancer treatment methods and new developments
Time of Update: 2022-11-05
6 months, and the survival status of patients was almost equivalent to that of second-line therapy 。 On June 9, 2021, Remegen's HER2-targeted ADC drug vedicitumab (RC48) was approved for marketing in China for the treatment of patients with HER2 overexpression locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least 2 systemic chemotherapy, breaking the situation that there are no original domestic new drugs in the field of ADC drugs, which is a milestone.
-
Prof. Jiajun Liu: Interpretation of the research progress of geratinib in the treatment of FLT3-mutated R/R AML patients
Time of Update: 2022-11-05
Gilteritinib is an oral, highly specific second-generation type I FMS-like tyrosine kinase 3 (FLT3) inhibitor capable of simultaneously inhibiting FLT3-ITD and FLT3-TKD mutations, and the phase III AD
-
The prospect of new drug treatment is promising - the treatment progress of peripheral T-cell lymphoma
Time of Update: 2022-11-05
4brief summaryIn conclusion, new drugs being evaluated in clinical trials, including novel PI3K inhibitors, JAK1 inhibitors and EZH1/EZH2 inhibitors, are expected to bring new dawn to patients with relapsed/refractory PTCL.
-
Nearly half of drug-resistant lung cancer patients have been relieved, and innovative precision therapies have demonstrated anti-cancer efficacy
Time of Update: 2022-11-05
Data analysis showed that NVL-520 has a good safety profile and tolerability, and shows preliminary efficacy in those patients with ROS1-positive non-small cell lung cancer (NSCLC) who have undergone a large number of pre-treatment, including those with brain metastases and G2032R resistance variants.
-
Gu Tianning, Hu Yongxian, Zhejiang University, et al.: B-cell malignant tumors recur after CAR-T cell therapy: challenges and future
Time of Update: 2022-11-05
Content introductionChinese Summary:Outline:As a new type of cellular immunotherapy, chimeric antigen receptor T (CAR-T) cell therapy has greatly changed the landscape of cancer treatment, especially in hematologic malignancies.
-
Nutritional support therapy for cancer patients under different treatment modalities (Part I)
Time of Update: 2022-11-05
Goals of nutritional therapy during chemotherapy in cancer patients include²:(1) maintain or improve dietary intake; (2) reduce metabolic disorders; (3) Maintain and increase skeletal muscle mass and maintain physical performance; (4) reduce the risk of dose reduction or treatment interruption during anti-tumor therapy; (5) Improve the quality of life.
-
10 indications for bevacizumab, usage and dosage, we summarized!
Time of Update: 2022-11-05
2. Non-small cell lung cancer (NSCLC)Bevacizumab plus platinum-based chemotherapy for first-line treatment of unresectable advanced, metastatic, or recurrent non-squamous NSCLC;Dosage: The recommended dose of bevacizumab is 15mg/kg body weight, administered once every 3 weeks (15 mg/kg/q3w);Note: Bevacizumab in combination with platinum-based chemotherapy for up to 6 cycles, followed by bevacizumab monotherapy until disease progression or intolerable toxicity.
